Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?

Oncoimmunology. 2014 Jan 1;3(1):e27482. doi: 10.4161/onci.27482. Epub 2014 Jan 3.

Abstract

Monoclonal antibodies that target immune checkpoints are undoubtedly changing the therapeutic landscape of different human malignancies. Here we comment on the effects of blocking cytotoxic T lymphocyte-associated protein 4 (CTLA4) by means of the monoclonal antibody tremelimumab in patients with refractory malignant mesothelioma, a deadly disease with no effective therapeutic options.

Keywords: anti-CTLA4 antibody; immunomodulating antibody; mesothelioma; therapy; tremelimumab.

Publication types

  • Research Support, Non-U.S. Gov't